Sorana Raiciulescu

Ms. Sorana Raiciulescu

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The Journal of Prosthetic Dentistry
Verified
Journal Article
Closed access
JTJoshua C. Treesh
Joshua C. Treesh
PLPeter C. Liacouras
Peter C. Liacouras
RTRobert M. Taft
Robert M. Taft
DBDaniel I. Brooks
Daniel I. Brooks
SRSorana Raiciulescu
Sorana Raiciulescu
LYLing Ye
Ling Ye

15 July 2022 in Ophthalmology Glaucoma
Verified
Journal Article
Closed access
RRRachel C. Ruda
Rachel C. Ruda
LYLucy Yuan
Lucy Yuan
GLGregory M. Lai
Gregory M. Lai
SRSorana Raiciulescu
Sorana Raiciulescu
WKWon I. Kim
Won I. Kim

9 August 2021 in Journal of Traumatic Stress
Verified
Journal Article
Closed access
PDF file
ASAlyssa Soumoff
Alyssa Soumoff
NCNeil G. Clark
Neil G. Clark
ESElizabeth A. Spinks
Elizabeth A. Spinks
PKPatricia A. Kemezis
Patricia A. Kemezis
SRSorana Raiciulescu
Sorana Raiciulescu
KCKwang Choi
Kwang Choi

15 February 2022 in The Journal of Emergency Medicine
Verified
Journal Article
Closed access
ASAlexis B. Sandler
Alexis B. Sandler
JSJohn P. Scanaliato
John P. Scanaliato
SRSorana Raiciulescu
Sorana Raiciulescu
LNLeon J. Nesti
Leon J. Nesti
JDJohn C. Dunn
John C. Dunn

12 May 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
FAFernanda Fortes De Araujo
Fernanda Fortes De Araujo
ILInes Lakhal-Naouar
Ines Lakhal-Naouar
NKNancy Koles
Nancy Koles
SRSorana Raiciulescu
Sorana Raiciulescu
RMRupal Mody
Rupal Mody
NANaomi Aronson
Naomi Aronson
Visceral leishmaniasis (VL) is a chronic infection caused by Leishmania (L.) donovani or L. infantum parasites. Despite having the infection, most individuals never develop the clinical disease and are able to control the parasite and remain asymptomatic. However, some progress to symptomatic VL, leading to death if untreated. The host immune response has a major role in determining the progression and severity of the clinical manifestations in VL; several immune biomarkers of symptomatic VL have been described with interferon-gamma release as a surrogate biomarker of host cellular immunity. However, new biomarkers to identify asymptomatic VL (AVL) are needed for the identification of people at risk for VL activation. In our study, levels of chemokine/cytokine in the supernatants of peripheral mononuclear blood cells (PBMC) from 35 AVL+ Iraq-deployed participants, stimulated in vitro with soluble Leishmania antigen for 72 h, were assessed by a bead-based assay that allows the measurement of multiple analytes. PBMC of AVL-negative military beneficiaries were used as controls. Monocyte Chemoattractant Protein-1, Monokine Induced by Gamma Interferon and Interleukin-8, were detected at high levels in AVL+ stimulated cultures from Iraq deployers compared to uninfected controls. Measurement of chemokine/cytokine levels can identify cellular immune responses in AVL+ asymptomatic individuals.

Verified
Journal Article
Open access
PDF file
SJSean Jin
Sean Jin
SKSharon Kim
Sharon Kim
JTJared Tallo
Jared Tallo
HRHarkaran S. Rana
Harkaran S. Rana
SRSorana Raiciulescu
Sorana Raiciulescu
WKWon I. Kim
Won I. Kim
Background/Objectives: This study evaluated the efficacy and safety of the ab externo open-conjunctiva (AEO) approach with adjunctive Ologen collagen matrix (OCM) compared to ab interno closed-conjunctiva (AIC) techniques for XEN45 gel stent implantation in patients with refractory open-angle glaucoma. The goal was to determine whether the AEO with OCM approach offers advantages in intraocular pressure (IOP) control and postoperative outcomes. Methods: A retrospective, comparative case series was conducted on 76 eyes from 76 patients with open-angle glaucoma who underwent XEN45 implantation between 2017 and 2022 at a single tertiary center. The patients were divided into Group 1 (AEO with OCM, n = 47) and Group 2 (AIC, n = 29). Postoperative IOP, the number of glaucoma medications, surgical complications, bleb revisions, and failure rates were recorded over 12 months. The AEO technique, supported by OCM, was assessed for its potential to reduce postoperative fibrosis and improve long-term outcomes. Results: Both groups experienced significant IOP reductions over time compared to baseline. However, Group 1 had superior outcomes, requiring fewer glaucoma medications postoperatively (p < 0.05), and demonstrated lower rates of complications (10.6% vs. 31.0%, p = 0.026) and bleb revisions (8.5% vs. 34.5%, p = 0.005). Kaplan–Meier survival analysis showed significantly greater cumulative surgical success in Group 1 compared to Group 2 (p < 0.001). Conclusions: The AEO with OCM approach to XEN45 implantation may provide improved safety and efficacy compared to the AIC approach. It appears to be beneficial in minimizing postoperative fibrosis, reducing the medication burden, and lowering complication and failure rates. Prospective randomized trials are needed to validate these findings.